Structures by: Aakeröy C. B.


Structures by: Aakeröy C. B.

Results: 429


#NameUnit Cell
1505170{1[(1-benzimidazolyl)methyl]-4[(1-pyrazolyl)methyl]benzene}2, succinic acid
Molecular Pharmaceutics (2007) 4, 3 317
a=5.6367(4)
b=32.910(3)
c=9.4476(7)
α= 90.00
β= 102.342(6)
γ= 90.00
V = 1712.1(2)
1505172MF-34-33 3-(4-pyridyl)pyrazole, (Me5-PhCOOH)2
Molecular Pharmaceutics (2007) 4, 3 317
a=8.8864(5)
b=11.9875(7)
c=13.7015(8)
α= 99.3800(10)
β= 93.1910(10)
γ= 107.5560(10)
V = 1364.42(14)
15051731-[(1-benzimidazolyl)methyl]-3-[(1-pyrazolyl)methyl]benzene (3,5-diNO2PhCOOH)2
Molecular Pharmaceutics (2007) 4, 3 317
a=9.7657(6)
b=11.7691(7)
c=14.0803(9)
α= 86.2270(10)
β= 74.1630(10)
γ= 86.2020(10)
V = 1551.53(17)
1506032hexyl bromo calixarene, acetonitrile
Organic letters (2006) 8, 12 2607-2610
a=10.7767(7)
b=11.6740(7)
c=20.8192(13)
α= 80.392(4)
β= 86.826(4)
γ= 76.503(3)
V = 2510.8(3)
1506033hexyl bromo calixarene, dichloromethane
Organic letters (2006) 8, 12 2607-2610
a=10.4432(15)
b=15.049(2)
c=16.320(2)
α= 90.00
β= 97.977(3)
γ= 90.00
V = 2540.0(6)
1506034NS 1 pentyl calixarene + acetonitrile
Organic letters (2006) 8, 12 2607-2610
a=18.3708(7)
b=18.3708(7)
c=19.8745(15)
α= 90.00
β= 90.00
γ= 90.00
V = 6707.4(6)
1506035NS 14 pentyl calixarene (+ octanedioic acid)
Organic letters (2006) 8, 12 2607-2610
a=23.3560(16)
b=22.1519(16)
c=25.5165(16)
α= 90.00
β= 94.302(4)
γ= 90.00
V = 13164.5(16)
2004810C8H12N,C9H10NO2
Acta Crystallographica Section C (1996) 52, 4 957-960
a=4.829(1)
b=5.843(1)
c=13.610(2)
α= 83.39(1)
β= 86.16(1)
γ= 82.63(2)
V = 377.78(12)
2005053C4H12N2,C4H4O6
Acta Crystallographica Section C (1996) 52, 6 1471-1473
a=6.4262(10)
b=9.1322(10)
c=9.3627(10)
α= 90
β= 108.850(10)
γ= 90
V = 519.98(12)
20151314-(dimethylamino)benzoic acid
Acta Crystallographica Section C (2005) 61, 12 o702-o704
a=9.6507(11)
b=9.8918(11)
c=10.0082(10)
α= 76.118(6)
β= 67.655(7)
γ= 69.334(9)
V = 820.61(16)
4105415SF22 4-pyridyl-CONH-(CH2)6)-NHCO-(4-pyridyl), succinic acid CHUNKS
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1754(4)
b=10.9294(8)
c=10.9423(8)
α= 118.826(4)
β= 91.381(5)
γ= 99.872(4)
V = 530.11(7)
4105416SF 2 4-pyridyl-CONH-(CH2)6-NHCO-4-pyridyl, HOOC-(CH2)4-COOH
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1412(4)
b=5.2394(4)
c=21.3961(17)
α= 95.094(5)
β= 95.603(4)
γ= 91.076(5)
V = 571.10(8)
4105417SF21 N,N'-(isonicotinyl)hexanediamine, octanedioic acid
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1392(5)
b=5.2412(5)
c=23.145(2)
α= 94.050(3)
β= 95.222(2)
γ= 91.277(2)
V = 619.03(10)
4105418SF3 (4-pyridyl)-CONH-(CH2)6-NHCO-(4-pyridyl), HOOC-(CH2)8-COOH
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1506(4)
b=5.2481(4)
c=24.5206(16)
α= 89.647(4)
β= 87.252(4)
γ= 88.505(5)
V = 661.82(8)
4105419SF5 (4-pyridyl)-CONH-(CH2)6-NHCO-(4-pyridyl), HOOC-(CH2)10-COOH
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1519(4)
b=5.2778(5)
c=26.148(3)
α= 86.023(6)
β= 89.386(6)
γ= 88.496(6)
V = 709.00(12)
4116829C4H4N4O2
Journal of the American Chemical Society (1998) 120, 8986-8993
a=4.1650(10)
b=6.6540(10)
c=21.293(4)
α= 90.00
β= 90.00
γ= 90.00
V = 590.1(2)
4117187C7H14N2O3
Journal of the American Chemical Society (1996) 118, 10134-10140
a=9.5230(10)
b=7.0500(10)
c=13.747(2)
α= 90.00
β= 96.730(10)
γ= 90.00
V = 916.6(2)
4117188C12H13N7O7
Journal of the American Chemical Society (1996) 118, 10134-10140
a=10.206(6)
b=7.598(5)
c=19.784(18)
α= 90.00
β= 94.86(5)
γ= 90.00
V = 1528.6(19)
4117189C5H7N3O3
Journal of the American Chemical Society (1996) 118, 10134-10140
a=6.162(3)
b=12.801(2)
c=8.7770(10)
α= 90.00
β= 96.61
γ= 90.00
V = 687.7(4)
4117190C9H11ClN2O3
Journal of the American Chemical Society (1996) 118, 10134-10140
a=15.6740(10)
b=12.1290(10)
c=11.429(2)
α= 90.00
β= 92.820(10)
γ= 90.00
V = 2170.1(4)
4302060(1,3-Ph2acac)Co(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9670(6)
b=11.2006(7)
c=15.3238(9)
α= 75.533(3)
β= 80.377(4)
γ= 79.221(4)
V = 1452.18(16)
4302061(1,3-Ph2acac)Ni(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9948(19)
b=11.185(2)
c=15.409(3)
α= 75.737(9)
β= 79.844(13)
γ= 78.971(16)
V = 1461.1(5)
4302062Cu{[4-(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide}2(F6-acac)2 (CH3CN)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.349(3)
b=10.688(3)
c=12.680(3)
α= 98.217(6)
β= 110.457(5)
γ= 104.465(5)
V = 1230.8(6)
4302063{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
Inorganic Chemistry (2009) 48, 4052-4061
a=9.7354(11)
b=11.1497(12)
c=23.870(3)
α= 90.00
β= 96.985(2)
γ= 90.00
V = 2571.8(5)
4302064bis{4-[(pyrazol-1-yl)methyl]benzamide} (Ph2-acac)2 Ni(II) bis{ethanol} (Ph2-acac)2 Ni(II)
Inorganic Chemistry (2009) 48, 4052-4061
a=9.0170(6)
b=12.3493(8)
c=17.6357(12)
α= 86.3190(10)
β= 78.0890(10)
γ= 72.2410(10)
V = 1830.0(2)
4302065{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.0325(10)
b=15.1765(15)
c=16.6440(16)
α= 90.00
β= 99.957(2)
γ= 90.00
V = 2496.0(4)
4302066527 4-[(2-phenylimidazol-1-yl)methyl]benzamide, mu-Cu2(F-PhCOO)4
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9536(9)
b=11.2155(8)
c=14.9765(12)
α= 77.570(6)
β= 78.159(4)
γ= 74.526(5)
V = 1710.1(2)
4302067528 3-[(2-phenylimidazol-1-yl)methyl]benzamide, Cu2(2-FC6H4COO)4 (CH3CN)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9819(16)
b=11.2072(15)
c=14.926(2)
α= 99.042(8)
β= 91.419(6)
γ= 116.183(7)
V = 1618.8(4)
4302068BS-2-11e mu(o-FPhCOO)4 Cu2[4-imidazolylmethylbenzamide]2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.8218(9)
b=19.4000(14)
c=12.0541(8)
α= 90.00
β= 108.346(4)
γ= 90.00
V = 2402.0(3)
4302069BS-3-44-2A 4-[(pyrazol-1-yl)methyl]PhCONH2, mu4-(AcO)Cu CH3CN
Inorganic Chemistry (2009) 48, 4052-4061
a=7.5896(5)
b=10.0990(7)
c=13.3959(8)
α= 68.531(4)
β= 82.310(3)
γ= 72.114(3)
V = 909.07(11)
4302070mu(OAc)4 Cu2 {3-[(pyrazol-1-yl)methyl]benzamide}2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.0173(4)
b=10.1615(5)
c=11.4846(6)
α= 110.1640(10)
β= 109.1250(10)
γ= 90.5040(10)
V = 821.95(7)
4309158(F6-acac)2[3-(2-amino-4-methoxypyrimidin-6-yl)pyridine]2Cu(II) (CHCl3)2
Inorganic Chemistry (2005) 44, 4983-4991
a=10.4149(6)
b=12.1682(7)
c=18.2488(10)
α= 105.6980(10)
β= 105.8970(10)
γ= 93.1160(10)
V = 2120.6(2)
4309159bis(1,3-Ph2propanedionato)-bis[3(2-amino-4-methoxypyrimidin-6-yl) pyridine]Co(II)
Inorganic Chemistry (2005) 44, 4983-4991
a=9.3368(7)
b=10.3686(8)
c=11.0609(8)
α= 85.536(2)
β= 79.677(2)
γ= 83.026(2)
V = 1043.95(14)
4309160bis(F6-acac)bis[3-(2-amino-4-methylpyrimidin-6-yl)pyridine]copper(II) 1,2-dichloroethane
Inorganic Chemistry (2005) 44, 4983-4991
a=8.2843(4)
b=10.8750(5)
c=11.7573(6)
α= 113.0810(10)
β= 94.4120(10)
γ= 103.8330(10)
V = 928.76(8)
43091611-(2-amino-4-methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne, Cu(F6-acac)2
Inorganic Chemistry (2005) 44, 4983-4991
a=9.6243(11)
b=10.4481(12)
c=13.8822(15)
α= 85.905(2)
β= 86.300(2)
γ= 74.690(2)
V = 1341.4(3)
4309162[1-(2-amino-4-Methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne]2, Co(PhCOCCOPh)2
Inorganic Chemistry (2005) 44, 4983-4991
a=10.5076(5)
b=10.7568(6)
c=11.9544(6)
α= 68.9160(10)
β= 82.6200(10)
γ= 69.1900(10)
V = 1178.48(11)
43091631-(2-amino-4-Methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne, Ni(Ph2acac)2
Inorganic Chemistry (2005) 44, 4983-4991
a=10.4666(7)
b=10.6669(7)
c=11.9828(8)
α= 68.678(4)
β= 82.626(4)
γ= 69.230(3)
V = 1165.27(14)
4501217PC-4-10e (2-aminopyrazine)2, 1,4-diiodotetrafluorobenzene
Crystal Growth & Design (2011) 11, 12 5333
a=7.9013(6)
b=5.6116(4)
c=20.1258(16)
α= 90.00
β= 101.260(4)
γ= 90.00
V = 875.18(12)
45012184-11e 2-amino-5-bromopyrazine, 1,4-diiodotetrafluorobenzene
Crystal Growth & Design (2011) 11, 12 5333
a=5.6316(6)
b=8.1219(9)
c=21.226(2)
α= 90.00
β= 93.035(4)
γ= 90.00
V = 969.50(17)
45012194-12e (3-amino-2,6-dibromopyrazine)2, 1,4-diiodotetrafluorobenzene
Crystal Growth & Design (2011) 11, 12 5333
a=5.6428(4)
b=9.7705(7)
c=10.4014(7)
α= 100.821(3)
β= 103.743(3)
γ= 93.752(3)
V = 543.49(7)
4504640[N-(2-pyridyl) acetamide]2, fumaric acid
Crystal Growth & Design (2006) 6, 2 474
a=4.8875(5)
b=8.4817(8)
c=11.4723(11)
α= 110.375(2)
β= 91.000(2)
γ= 96.451(2)
V = 442.18(7)
4504641[N-(2-pyridyl)acetamide]2, succinic acid
Crystal Growth & Design (2006) 6, 2 474
a=9.1172(8)
b=9.2969(8)
c=10.6430(9)
α= 90.00
β= 92.694(2)
γ= 90.00
V = 901.12(13)
4504645[N-(2-pyridyl)acetamide]2, nonanedioic acid
Crystal Growth & Design (2006) 6, 2 474
a=16.563(3)
b=8.5279(12)
c=18.464(3)
α= 90.00
β= 114.909(9)
γ= 90.00
V = 2365.4(7)
4504646[N-(2-pyridyl)acetamide]2, decanedioic acid
Crystal Growth & Design (2006) 6, 2 474
a=5.3767(4)
b=6.5416(4)
c=17.0662(12)
α= 92.8090(10)
β= 90.2470(10)
γ= 101.3140(10)
V = 587.82(7)
4504647N-(3-pyridyl)acetamide, 5-nitroisophthalic acid
Crystal Growth & Design (2006) 6, 2 474
a=19.5362(14)
b=9.3631(7)
c=12.7665(10)
α= 90.00
β= 113.382(4)
γ= 90.00
V = 2143.5(3)
4504813(4-bromo-phenylacetonitrile oxime)2, 1,4-di[(1-benzimidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=11.436(4)
b=5.640(2)
c=26.449(9)
α= 90.00
β= 99.252(5)
γ= 90.00
V = 1683.7(10)
4504814(4-bromo-phenylacetonitrile oxime)2, 1,4-di[(1-imidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=12.9436(5)
b=5.1863(2)
c=21.6419(9)
α= 90.00
β= 93.4500(10)
γ= 90.00
V = 1450.17(10)
4504815(4-bromo-PhC(CN)(=NOH))2, 1,4-di[(2-methyl-1-benzimidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=7.4360(9)
b=19.613(2)
c=12.5107(15)
α= 90.00
β= 107.063(2)
γ= 90.00
V = 1744.3(3)
4504816(4-bromo-PhC(CN)(=NOH))2, 1,4-di[(2-methyl-1-imidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=7.0034(8)
b=10.6013(12)
c=11.1605(12)
α= 77.000(2)
β= 75.995(2)
γ= 84.920(2)
V = 782.87(15)
4504817(3-chloro-phenylacetonitrile oxime)2, 1,4-di[(1-imidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=5.9000(10)
b=7.2231(12)
c=17.088(3)
α= 86.114(3)
β= 89.633(4)
γ= 73.472(3)
V = 696.5(2)
45048181,4-[bis(2-methylbenzimidazol-1-yl)methyl]benzene, (4-bromobenzacetoxime)2
Crystal Growth & Design (2006) 6, 4 1033
a=10.9286(11)
b=14.1612(15)
c=11.3704(12)
α= 90.00
β= 92.619(2)
γ= 90.00
V = 1757.9(3)
45048603-[(benzimidazol-1-yl)methyl]benzamide
Crystal Growth & Design (2005) 5, 3 1283
a=9.2133(11)
b=11.6848(13)
c=12.1071(15)
α= 104.058(9)
β= 98.623(8)
γ= 94.900(7)
V = 1239.9(3)
45048623-[(2-chlorobenzimidazol-1-yl)methyl]-benzamide
Crystal Growth & Design (2005) 5, 3 1283
a=8.8067(7)
b=11.8803(12)
c=14.0856(15)
α= 74.800(4)
β= 72.485(5)
γ= 68.786(4)
V = 1290.5(2)
45048643-[(benzimidazol-1-yl)methyl]benzamide, 4-nitrobenzoic acid
Crystal Growth & Design (2005) 5, 3 1283
a=7.5178(9)
b=9.1850(11)
c=15.0850(15)
α= 105.516(6)
β= 100.600(7)
γ= 100.339(8)
V = 957.4(2)
45048653-[(2-methylbenzimidazol-1-yl)methyl]PhCOOH,(4-NO2PhCOOH)2
Crystal Growth & Design (2005) 5, 3 1283
a=7.5292(5)
b=11.0980(8)
c=17.2512(11)
α= 81.865(4)
β= 77.854(3)
γ= 74.581(4)
V = 1352.89(16)
4505658isonicotinamide : 4-nitrobenzoic acid
Crystal Growth & Design (2003) 3, 2 159
a=20.512(4)
b=5.1675(10)
c=23.694(5)
α= 90.00
β= 90.66(3)
γ= 90.00
V = 2511.3(9)
45056593,5-dinitrobenzoic acid : isonicotinamide : 4-toluic acid
Crystal Growth & Design (2003) 3, 2 159
a=7.7628(11)
b=8.7216(12)
c=15.7426(19)
α= 93.483(2)
β= 98.981(3)
γ= 93.913(2)
V = 1047.6(2)
45056602-amino-5-nitropyrimidine : 2-amino-3-nitropyridine
Crystal Growth & Design (2003) 3, 2 159
a=11.786(3)
b=5.1614(13)
c=19.975(5)
α= 90.00
β= 95.275(5)
γ= 90.00
V = 1210.0(5)
45056614-Chlorobenzamide : 3,5-Dinitrobenzoic acid
Crystal Growth & Design (2003) 3, 2 159
a=7.2458(11)
b=8.6260(13)
c=13.2806(19)
α= 92.566(3)
β= 101.875(3)
γ= 109.472(3)
V = 760.0(2)
45056632(4-Chlorobenzamide) : Fumaric acid
Crystal Growth & Design (2003) 3, 2 159
a=9.2674(8)
b=10.1386(9)
c=10.4805(10)
α= 86.428(6)
β= 72.174(6)
γ= 89.506(7)
V = 935.58(15)
4505858CuCl4 + 2DMANH
Crystal Growth & Design (2001) 1, 6 485
a=9.900(4)
b=9.926(1)
c=16.705(3)
α= 83.825(12)
β= 86.673(23)
γ= 71.387(19)
V = 1546.2(7)
4505859CuBr4 + 2DMANH
Crystal Growth & Design (2001) 1, 6 485
a=9.6535(9)
b=9.7211(11)
c=19.3952(17)
α= 75.645(9)
β= 77.522(6)
γ= 65.741(9)
V = 1594.1(3)
4505860ZnCl4 + 2DMANH
Crystal Growth & Design (2001) 1, 6 485
a=15.237(3)
b=11.774(2)
c=17.443(4)
α= 90.00
β= 94.113(4)
γ= 90.00
V = 3121.2(11)
4505861Cu2Cl6 + 2PSPG
Crystal Growth & Design (2001) 1, 6 485
a=14.816(3)
b=12.460(2)
c=18.734(3)
α= 90.00
β= 93.95(3)
γ= 90.00
V = 3450.2(11)
4506067SVP-4N-AA (4-pyridyl)-CONH-(2-pyridyl), HOOC-(CH2)4-COOH
Crystal Growth & Design (2012) 12, 5 2579
a=11.9508(11)
b=19.8752(19)
c=7.3996(8)
α= 90.00
β= 105.384(4)
γ= 90.00
V = 1694.6(3)
4506070SVP-4N-SUC (4-pyridyl)-CONH-(2-pyridyl), HOOC-(CH2)2-COOH
Crystal Growth & Design (2012) 12, 5 2579
a=11.2578(7)
b=19.6623(11)
c=19.8130(12)
α= 93.236(3)
β= 91.236(3)
γ= 90.298(3)
V = 4377.6(5)
4506075SVP-3N-PA (3-pyridyl)-CONH-(2-pyridyl), HOOC-(CH2)5-COOH
Crystal Growth & Design (2012) 12, 5 2579
a=7.5711(5)
b=11.9820(8)
c=20.1758(13)
α= 82.560(4)
β= 80.081(4)
γ= 85.195(4)
V = 1784.2(2)
4507105EH-4-97-4 4-Br-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=7.6597(9)
b=13.4779(16)
c=13.7575(16)
α= 117.048(4)
β= 90.413(5)
γ= 90.972(4)
V = 1264.6(3)
4507106EH-1-25-05 4-CN-PhCOOH, 4-I-pyrazole
Crystal Growth & Design (2012) 12, 11 5806
a=6.7767(5)
b=8.0047(6)
c=11.1806(10)
α= 83.315(4)
β= 77.745(4)
γ= 85.862(4)
V = 587.94(8)
4507107EH-01-25-06 3,5-(NO2)2-PhCOOH, 4-I-pyrazole
Crystal Growth & Design (2012) 12, 11 5806
a=10.1937(6)
b=11.2088(6)
c=13.1357(7)
α= 111.112(2)
β= 108.116(2)
γ= 92.381(2)
V = 1310.62(13)
4507108EH-6-65-12 3,5-Me2-4-Cl-pyrazole, 3-MeO-4-HO-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=12.8138(7)
b=7.2047(4)
c=15.2522(9)
α= 90.00
β= 90.00
γ= 90.00
V = 1408.08(14)
4507109EH-6-65-11 3,5-Me2-4-Cl-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=6.4021(4)
b=7.8731(5)
c=28.0067(19)
α= 90.00
β= 90.195(3)
γ= 90.00
V = 1411.65(16)
4507110EH-4-45-3 3,5-Me2-4-Br-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=6.4192(7)
b=8.0239(8)
c=28.206(3)
α= 90.00
β= 90.00
γ= 90.00
V = 1452.8(3)
4507111EH-6-65-6 (3,5-Me2-4-Cl-pyrazole)2, 2,4-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=9.3369(18)
b=10.489(2)
c=11.923(2)
α= 77.852(12)
β= 75.218(11)
γ= 68.606(12)
V = 1042.3(3)
4507112EH-6-65-23 3,5-Me2-4-I-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=7.1993(5)
b=7.8251(6)
c=13.4055(10)
α= 93.999(3)
β= 90.564(3)
γ= 96.990(3)
V = 747.64(10)
4507113EH-4-90-1 pyrazole, 3,5-Cl2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=7.7111(12)
b=9.6247(14)
c=14.275(2)
α= 73.355(8)
β= 89.353(9)
γ= 68.778(7)
V = 941.1(2)
4507114EH-3-93-7 pyrazole, [(NO2)2-PhCOOH]2
Crystal Growth & Design (2012) 12, 11 5806
a=7.1717(6)
b=13.2773(12)
c=20.7542(16)
α= 90.00
β= 92.463(4)
γ= 90.00
V = 1974.4(3)
4507115EH-3-94-1 3,5-Me2-pyrazole, 3,5-dinitrobenzoic acid hydrate
Crystal Growth & Design (2012) 12, 11 5806
a=8.6114(4)
b=6.2504(3)
c=27.4741(13)
α= 90.00
β= 94.822(3)
γ= 90.00
V = 1473.55(12)
7006759bis(2-amino-4-(3-pyridyl)-6-methylpyrimidine) mu- (OAc)4dicopper(ii)
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.0282(5)
b=10.6399(7)
c=18.9041(13)
α= 90.00
β= 99.3600(10)
γ= 90.00
V = 1593.27(18)
7006760bis(2-amino-4-(3-pyridyl)-6-methoxypyrimidine) mu-(OAc)4 dicopper(ii)
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.2800(6)
b=9.3983(6)
c=11.2233(7)
α= 71.144(4)
β= 81.585(4)
γ= 79.240(4)
V = 808.49(10)
7006761(2-amino-4-(3-pyridyl)-6-methoxypyridine)2, (2- fluorobenzoate)4 Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=10.1310(9)
b=10.5499(8)
c=12.2936(9)
α= 64.853(5)
β= 86.149(5)
γ= 67.896(4)
V = 1095.24(16)
7006762(2-amino-4-(3-pyridyl)-6-methylpyridine)2, (2FPhCOO)4 Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=21.3553(18)
b=17.9389(15)
c=11.4887(9)
α= 90.00
β= 90.742(5)
γ= 90.00
V = 4400.8(6)
70067631-(2-NH2-4-pyrimidyl)-2-(3-methoxy-5-pyridyl)ethyne (AcO)4Cu2 (EtO).6 (CH3CN).8
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=7.6304(13)
b=11.3870(19)
c=12.341(2)
α= 76.216(3)
β= 84.191(3)
γ= 79.459(3)
V = 1022.0(3)
70067641-(2-NH2-5-pyridyl)-2-(3-pyridyl)-ethyne, (2FPhCOO)4Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=9.3471(9)
b=15.5850(15)
c=12.9025(11)
α= 90.00
β= 104.714(7)
γ= 90.00
V = 1817.9(3)
70067651-(2-NH2-5-pyridyl)-2-(3-pyridyl)-ethyne, (CH3COO)4Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.1368(11)
b=8.3062(11)
c=8.7490(12)
α= 86.244(3)
β= 80.480(3)
γ= 80.539(3)
V = 574.79(13)
7008557bis(4-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4, H2O
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=40.141(3)
b=4.9633(5)
c=18.6857(19)
α= 90.00
β= 96.855(6)
γ= 90.00
V = 3696.2(6)
7008558bis(3-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.666(2)
b=12.237(2)
c=13.013(2)
α= 109.136(13)
β= 114.266(8)
γ= 92.310(14)
V = 1566.6(5)
7008559bis(4-((6,7-dimethylbenzimidazol-1-yl)methyl)benzamide), AgBF4
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.9140(7)
b=8.4229(6)
c=19.7055(13)
α= 90.00
β= 102.108(3)
γ= 90.00
V = 1608.89(19)
7008560bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (AsF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.3084(4)
b=18.5828(11)
c=25.1620(15)
α= 90.00
β= 96.8060(10)
γ= 90.00
V = 3393.2(3)
70085613-((2-methylbenzimidazol-1-yl)methyl)benzamide, Ag (AsF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.8443(8)
b=12.1157(7)
c=13.3329(8)
α= 66.333(3)
β= 69.670(3)
γ= 87.960(3)
V = 1631.16(18)
7008562(4-((5,6-dimethylbenzimidazol-1-yl)methyl)benzamide)2, AgAsF6
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.1269(6)
b=9.2459(5)
c=10.0615(7)
α= 97.921(4)
β= 89.950(4)
γ= 98.904(4)
V = 830.64(9)
7008563bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.5069(5)
b=18.6924(12)
c=24.9808(17)
α= 90.00
β= 98.4920(10)
γ= 90.00
V = 3466.9(4)
7008564bis(2-methyl-3-((benzamide-3-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.2644(4)
b=13.2045(6)
c=14.2022(6)
α= 74.5580(10)
β= 81.7510(10)
γ= 72.2750(10)
V = 1591.47(12)
7009747C7H7ClCuNO2
Journal of the Chemical Society, Dalton Transactions (2000) 21 3869
a=3.8105(16)
b=15.819(7)
c=13.311(6)
α= 90.00
β= 96.045(7)
γ= 90.00
V = 797.9(6)
7009748C7H7CuINO2
Journal of the Chemical Society, Dalton Transactions (2000) 21 3869
a=4.0964(11)
b=13.656(5)
c=16.114(5)
α= 90.00
β= 92.225(6)
γ= 90.00
V = 900.7(5)
7013465copper(ii)(isonicotinamide)diacetate
Dalton Trans. (2003) 20 3956-3962
a=7.1996(10)
b=8.1027(12)
c=13.4485(19)
α= 90.408(2)
β= 96.328(3)
γ= 96.118(2)
V = 775.17(19)
7013466copper(ii)bis(isonicotinamide)bis(2-fluorobenzoate)
Dalton Trans. (2003) 20 3956-3962
a=7.4814(12)
b=7.7279(14)
c=12.586(2)
α= 72.762(3)
β= 72.803(3)
γ= 77.970(3)
V = 658.07(19)
7013467copper(ii)(isonicotinamide)diacetate
Dalton Trans. (2003) 20 3956-3962
a=9.3053(17)
b=10.1542(19)
c=12.885(2)
α= 69.735(3)
β= 75.696(3)
γ= 67.129(3)
V = 1043.4(3)
7013468copper(ii)bis(isonicotinamide)diacetate diacetic acid
Dalton Trans. (2003) 20 3956-3962
a=11.0398(15)
b=15.245(2)
c=15.650(2)
α= 90.00
β= 104.910(3)
γ= 90.00
V = 2545.2(6)
7013469bis(isonicotinamide)-bis(2-fluorobenzoate)(2-fluorobenzoic acid)copper(ii)
Dalton Trans. (2003) 20 3956-3962
a=11.0792(14)
b=19.771(2)
c=15.5280(19)
α= 90.00
β= 104.284(3)
γ= 90.00
V = 3296.2(7)